Navigation Links
Enobia Announces Positive Clinical Results With ENB-0040, a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia
Date:9/14/2009

tudy have opted to continue treatment under a long-term extension protocol, and we have amended the initial study to include an additional five patients. We will also begin enrollment of a Phase 2 study in children aged five to 12 years in the weeks ahead."

Study Design and Findings

The infant study was designed to assess the safety, tolerability and efficacy of ENB-0040 in infants with HPP. Subjects received an initial intravenous dose of ENB-0040, followed by subcutaneous injections three times weekly for six months.

Three severely affected infants and two young children completed six months of treatment. There were no deaths or drug-related serious adverse events. Subcutaneous dosing was well tolerated, and no anti-ENB-0040 antibodies were detected. At six months, four of five patients with severe rickets treated with ENB-0040 showed marked radiographic, respiratory and functional improvement, while the fifth and most severely affected showed functional improvement and changes in biochemical markers suggesting bone remineralization. Notably, no new fractures were reported.

About Hypophosphatasia

Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease. Affected individuals have low levels of the tissue non-specific form of alkaline phosphatase, an essential regulator of bone mineralization, leading to rickets in infants and children and osteomalacia ("soft bones" resulting from poor mineralization) in adults. Disease severity is inversely proportional to the age at symptom onset. Clinical severity ranges from the severe perinatal or infantile forms, with marked skeletal hypomineralization and respiratory compromise often causing death, to a persistent and debilitating osteomalacia in adults.

In the infantile form, infants may appear normal at birth but develop serious symptoms in the first six months of life. These can include failur
'/>"/>

SOURCE Enobia Pharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
2. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
3. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
4. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
5. Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial
6. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
7. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
8. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
9. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
10. ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
11. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... 11, 2011 Tonight,s "Dan Rather Reports" examines ... of antibiotics. Every year, more than 90,000 Americans ... antibiotic-resistant infections, caused directly by the overuse of ... $35 billion a year.  In tonight,s program, Dan ...
... 2011 WebMD Health Corp. (Nasdaq: WBMD ) ... million aggregate principal amount of 2.50% Convertible Notes due 2018 ... the exercise in full of the initial purchaser,s over-allotment option). ... to Rule 144A under the Securities Act of 1933.   ...
Cached Medicine Technology:Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 2Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 3Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 4WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... have alerted the public about toxic carrot juice supplied ... Canadians// due to the contamination caused by the botulism ... by Bolthouse Farms, nearly 10 Toronto Businesses continued to ... States nearly four were hospitalized after consuming the juice, ...
... may be governed by her ovaries according to a new ... Claire// showed that women put more time and effort into ... a woman’s clothes and makeup affected at that time of ... men and each other alter as well. ,Study's ...
... dengue fever grips the country, another viral disease chikungunya ... //have been reported across nine states. ,Though Delhi ... worst hit is Karnataka with over 756,028 suspected cases ... ,Maharashtra has 262,595 suspected and 679 confirmed cases. ...
... indeed a wake-up call to the food and drug watchdog, ... in the market. This has been put forth vociferously by ... advisory panel. ,A report enabled by The Institute ... the FDA with more manpower, finance and authority to be ...
... For Health Technologies Inc., makers of IntelliFill i.v.?, ... IV medications in syringes//, announced today that Children’s ... producing over three million syringes using the IntelliFill ... October 2002. The hospital’s inpatient pharmacy is currently ...
... Dr Mukesh Haikerwal, said today the Government must make ... to be truly effective in meeting the needs of ... were announced today by the Prime Minister, and the ... care. ,While the AMA is generally pleased ...
Cached Medicine News:Health News:Women’s Fashion Sense Linked to Her Ovulatio 2Health News:Medical Center Tops 3 Million IV Syringes Using IntelliFill i.v. Robotics 2Health News:Mental Health Package Regrettably Undervalues the Role of the GP 2
... True/Flex Upper Extremity Intramedullary Rod System offers ... to conventional methods of rodding and plating. ... at the fracture site and enhanced healing4 ... to be easily inserted into the canal. ...
Interphlex Flexible Stablization Rods offer correction of Hammer Toes with a High level of Flexibility while maintaining correct toe length and shape....
The True/Fix Compression Hip Screw System offers a wide variety of plate and screw sizes available....
... Simple, cost-effective microfiltration for your transfusion ... also brings you an easy and ... of microfiltration for a variety of ... postoperative applications, autologous or homologous transfusions, ...
Medicine Products: